The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult Subjects.

Behm, Martin O; Kosoglou, Teddy; Miltenburg, André M M; Li, Jing; Statkevich, Paul; Johnson-Levonas, Amy O; Martinho, Monika; Fackler, Paul

Behm, Martin O; Kosoglou, Teddy; Miltenburg, André M M; Li, Jing; Statkevich, Paul; Johnson-Levonas, Amy O; Martinho, Monika; Fackler, Paul.

Afiliación

Behm MO; Merck & Co., Inc., Whitehouse Station, NJ, USA.
Kosoglou T; Merck & Co., Inc., Whitehouse Station, NJ, USA.
Miltenburg AM; Merck & Co., Inc., Whitehouse Station, NJ, USA.
Li J; Merck & Co., Inc., Whitehouse Station, NJ, USA.
Statkevich P; Merck & Co., Inc., Whitehouse Station, NJ, USA.
Johnson-Levonas AO; Merck & Co., Inc., Whitehouse Station, NJ, USA.
Martinho M; Merck & Co., Inc., Whitehouse Station, NJ, USA.
Fackler P; Merck & Co., Inc., Whitehouse Station, NJ, USA.

Clin Pharmacol Drug Dev ; 2(4): 310-5, 2013 Oct.

Article en En | MEDLINE | ID: mdl-27121935

Palabras clave

PAR-1; food; interaction; pharmacokinetics; vorapaxar

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2013 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google